MW 244.29 Da, Purity >98%. Agonist at GABAA receptors containing β3 subunits. Anaesthetic and amnesic properties.
1,8-cineole 2-exo-monooxygenase, ALDOS, Albendazole monooxygenase, Albendazole sulfoxidase, Aldosterone synthase, Aldosterone-synthesizing enzyme, C11B2_HUMAN, CAE 2, CP33, CP34, CP3A4_HUMAN, CYP11B, CYP11B2, CYP3, CYP3A, CYP3A3, CYP3A4, CYPIIIA3, CYPIIIA4, CYPXIB1, CYPXIB2, Cytochrome P 450c11, Cytochrome P-450Aldo, Cytochrome P-450C18, Cytochrome P450 11B1, mitochondrial, Cytochrome P450 11B2, Cytochrome P450 11B2, mitochondrial, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 HLp, Cytochrome P450 NF-25, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450, family 11, subfamily B, polypeptide 1, Cytochrome P450, subfamily XIB (steroid 11 beta hydroxylase), polypeptide 1, Cytochrome P450, subfamily XIB, polypeptide 1, Cytochrome P450-PCN1, Cytochrome p450 XIB1, ECA 2, ECA4, EIEE19, EJM, EJM5, FHI, GABA, GABA A receptor subunit alpha 2, GABA(A) receptor, GABA(A) receptor beta 2, GABA(A) receptor gamma 2, GABA(A) receptor subunit alpha-1, GABA(A) receptor subunit alpha-2, GABA(A) receptor subunit beta-2, GABA(A) receptor subunit gamma-2, GABA(A) receptor, alpha 1, GABA-A receptor, beta-2 polypeptide, GABR A2, GABRA 1, GABRA2 protein, GABRB2, GABRG 2, GBRA1_HUMAN, GBRA2_HUMAN, GBRB2_HUMAN, GBRG2_HUMAN, GEFSP 3, Gaba receptor alpha 1 polypeptide, Gamma aminobutyric acid (GABA) A receptor alpha 1, Gamma aminobutyric acid (GABA) A receptor alpha 2, Gamma aminobutyric acid (GABA) A receptor gamma 2, Gamma aminobutyric acid (GABA) A receptor, beta 2, Gamma aminobutyric acid A receptor alpha 1, Gamma aminobutyric acid A receptor alpha 2, Gamma aminobutyric acid A receptor beta 2, Gamma aminobutyric acid A receptor gamma 2, Gamma aminobutyric acid receptor alpha 2 subunit, Gamma aminobutyric acid receptor gamma 2 subunit, Gamma aminobutyric acid type A receptor alpha1 subunit, Gamma-aminobutyric acid receptor subunit alpha-1, Gamma-aminobutyric acid receptor subunit alpha-2, Gamma-aminobutyric acid receptor subunit gamma-2, Gamma-aminobutyric-acid receptor subunit beta-2, Glucocorticoid inducible P450, HLP, MGC126680, NF 25, Nifedipine oxidase, P 450C11, P-450Aldo, P-450C18, P450 III steroid inducible, P450 PCN1, P450, family III, P450C3, Quinine 3-monooxygenase, S11BH, Steroid 11 beta hydroxylase, Steroid 11 beta monooxygenase, Steroid 18-hydroxylase, Taurochenodeoxycholate 6-alpha-hydroxylase, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, mitochondrial
MW 244.29 Da, Purity >98%. Agonist at GABAA receptors containing β3 subunits. Anaesthetic and amnesic properties.
Soluble in DMSO to 100 mM.
Soluble in ethanol to 500 mM.
Soluble in 1 eq. HCl to 100 mM (with heating).
Soluble in water to 1 mM.
Agonist at GABAA receptors containing β3 subunits. Anaesthetic and amnesic properties.
Cytochrome P450 3A4 also known as CYP3A4 is an important enzyme in the metabolism of many drugs and xenobiotics. It has a molecular weight of approximately 57 kDa and is primarily expressed in the liver and small intestine. CYP3A4 plays a critical role in the metabolic clearance of around 50% of all clinically prescribed drugs. Alongside its cousins like CYP3A5 it is involved in the oxidative metabolism of bilirubin and various hormones. Additionally the subfamily of GABA A receptors including GABRB2 GABRG2 GABRA1 and GABRA2 function as chloride channels activated by gamma-aminobutyric acid (GABA) a major inhibitory neurotransmitter in the central nervous system.
These GABA A receptors form pentameric complexes that modulate synaptic transmission. They are responsible for reducing neuronal excitability throughout the nervous system. They are essential for calming neural circuits and are modulated by several ligands and drugs like benzodiazepines. The modulation of these receptors can alter mood anxiety and epileptic states. In the adrenal cortex enzymes such as CYP11B1 also known as steroid 11β-hydroxylase and CYP11B2 also known as aldosterone synthase are involved in steroidogenesis converting cholesterol into glucocorticoids and mineralocorticoids important for stress response and electrolyte balance.
CYP3A4 is prominent in the drug metabolism pathway and interacts closely with various drugs altering their efficacy and toxicity. The GABA A receptors on the other hand partake in the inhibitory neurotransmission pathway important for maintaining neural circuit balance. CYP3A4 shares pathways with proteins like CYP2D6 while GABA A receptors are interlinked with associated proteins like GABARAP (GABA receptor-associated protein) that aid in receptor trafficking and function.
The malfunction or dysregulation of these proteins can lead to significant health issues. CYP3A4's altered activity can result in drug-related adverse effects or toxicities impacting neuronal and systemic functions. The GABA A receptors are associated with neurological disorders including epilepsy and anxiety disorders. Mutations or irregular expression of GABRB2 or GABRG2 can disrupt normal brain function links them to these disorders. CYP11B1 and CYP11B2 involve disorders like congenital adrenal hyperplasia and primary aldosteronism causing hormonal imbalances that affect blood pressure and immune response.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab120311, Etomidate, GABAA agonist
ab7977 staining BAX in RAW 264.7 cells treated with etomidate (ab120311), by ICC/IF. Increase in BAX expression correlates with increased concentration of etomidate, as described in literature.
The cells were incubated at 37°C for 24h in media containing different concentrations of ab120311 (etomidate) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab7977 (1 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (Goat Anti-Rabbit IgG H&L (DyLight® 488) preadsorbed ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com